Structure-Based Discovery of Novel Chemotypes for Adenosine A2AReceptor Antagonists
Citations Over TimeTop 1% of 2010 papers
Abstract
The recent progress in crystallography of G-protein coupled receptors opens an unprecedented venue for structure-based GPCR drug discovery. To test efficiency of the structure-based approach, we performed molecular docking and virtual ligand screening (VLS) of more than 4 million commercially available "drug-like" and ''lead-like'' compounds against the A(2A)AR 2.6 A resolution crystal structure. Out of 56 high ranking compounds tested in A(2A)AR binding assays, 23 showed affinities under 10 microM, 11 of those had sub-microM affinities and two compounds had affinities under 60 nM. The identified hits represent at least 9 different chemical scaffolds and are characterized by very high ligand efficiency (0.3-0.5 kcal/mol per heavy atom). Significant A(2A)AR antagonist activities were confirmed for 10 out of 13 ligands tested in functional assays. High success rate, novelty, and diversity of the chemical scaffolds and strong ligand efficiency of the A(2A)AR antagonists identified in this study suggest practical applicability of receptor-based VLS in GPCR drug discovery.
Related Papers
- → A2A and A2B adenosine receptors: The extracellular loop 2 determines high (A2A) or low affinity (A2B) for adenosine(2019)40 cited
- → Regulation of Cardiovascular Development by Adenosine and Adenosine-Mediated Embryo Protection(2012)21 cited
- → Advances in the effect of adenosine A2 receptor activation in the prevention and treatment of ischemic diseases(2018)1 cited
- → Evidence for an adenosine A2/Ra receptor on human basophils(1985)35 cited
- → Human Placental Adenosine A2-Like Binding Sites Properties and Homology with Mammalian and Avian Stress Proteins(1990)